Medical (n = 45) | BAE (n = 33) | P-value | |
---|---|---|---|
Male sex | 12 (26.7) | 15 (45.5) | 0.098 |
Age, years, at diagnosis | 59.5 ± 11.7 | 60.0 ± 12.1 | 0.855 |
BMI, kg/m2 | 20.5 ± 2.6 | 19.8 ± 2.9 | 0.274 |
Diabetes mellitus | 2 (4.4) | 4 (12.1) | 0.392 |
Hypertension | 8 (17.8) | 7 (21.2) | 0.704 |
Performed bronchoscopy | 28 (62.2) | 24 (72.7) | 0.466 |
Type of chest CT | |||
Nodular bronchiectatic | 38 (84.4) | 28 (84.8) | 0.961 |
Fibrocavitary | 7 (15.6) | 5 (15.2) | |
> 3 lobe distribution of chest CT | 8 (17.8) | 12 (36.4) | 0.073 |
Antiplatelet/anticoagulation therapy | 5 (11.1) | 5 (15.2) | 0.735 |
Liver disease | 4 (8.9) | 5 (15.2) | 0.726 |
History of pulmonary tuberculosis | 15 (33.3) | 16 (48.5) | 0.242 |
Charlson Comorbidity Index score | 1.04 ± 1.1 | 1.6 ± 2.0 | 0.119 |
2 NTM pathogens identified | 4 (8.9) | 1 (3.0) | 0.389 |
Complication after BAE | 0 | ||
Repeat BAE due to rebleeding | 8 (24.2) | ||
Duration between first BAE and rebleedinga | 10 (7.5–53.5)a | ||
Number of BAE trials | |||
1 | 25 (75.8) | ||
2 | 5 (15.2) | ||
5 | 2 (6.1) | ||
8 | 1 (3.0) |